Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety through its INTERCEPT Blood System and related technologies. This news page aggregates company announcements, financial updates, clinical milestones, and partnership news that Cerus releases through channels such as Business Wire and SEC-furnished press releases.
Readers can find coverage of quarterly and annual financial results, where Cerus reports product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, along with government contract revenue tied to research and development programs. These releases often include updated product revenue guidance ranges and commentary on commercial performance in various geographies.
The news flow also highlights clinical and regulatory developments, including progress of the INTERCEPT red blood cell system in late-stage clinical development, Phase 3 trials such as RedeS, and regulatory review activities in Europe and the United States. Updates on the INT200 LED-based illumination device and development of lyophilized IFC (LyoIFC), supported by U.S. Department of Defense funding, are also featured.
In addition, Cerus issues news about strategic collaborations and industry engagement, such as group purchasing agreements with organizations like Blood Centers of America and participation in professional meetings, workshops, and conferences in transfusion medicine. These items describe efforts to expand access to pathogen-protected blood components and to share data on INTERCEPT technologies.
Investors, clinicians, and other stakeholders can use this page to follow Cerus’ latest disclosures on product adoption, revenue trends, government-supported projects, and scientific presentations related to blood safety and pathogen reduction.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2021 financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for 4:30 PM ET on the same day, where management will discuss the financial results and provide a business overview. The INTERCEPT Blood System, the company's flagship product, remains the only pathogen reduction system with CE mark and FDA approval for platelets and plasma. A replay of the call will be available post-event until November 16, 2021.
Today, the FDA's final guidance on bacterial risk control for platelet collection and transfusion takes effect, promoting the INTERCEPT Blood System for platelets by Cerus (CERS) as a compliant pathogen reduction solution. This system not only addresses bacterial contamination—recognized as a major risk in the U.S.—but also inactivates a range of viruses and parasites. The guidance aims to enhance platelet safety and availability for transfusions across the U.S., marking a significant milestone in transfusion medicine, as INTERCEPT is currently the only FDA-approved measure for compliance.
Cerus Corporation (NASDAQ: CERS) will participate in the Society for the Advancement of Blood Management Annual Meeting from September 22-25, 2021. On September 23, Cerus will host a workshop discussing the clinical need for the INTERCEPT Fibrinogen Complex, featuring presentations from hospital customers. The INTERCEPT Blood System for Cryoprecipitation is FDA approved since November 2020, aimed at improving treatment of massive hemorrhage. Additionally, CMS has granted a New Technology Add-On Payment for the INTERCEPT Fibrinogen Complex.
Cerus Corporation (Nasdaq: CERS) announces participation in the 2021 Cantor Global Virtual Healthcare Conference on September 29, 2021, at 11:20 a.m. ET. CEO William 'Obi' Greenman and CFO Kevin D. Green will represent the company. A live webcast will be accessible on Cerus’ Investor Relations page, with a replay available for two weeks post-event. Cerus is committed to protecting the global blood supply, offering the INTERCEPT Blood System, which has CE mark and FDA approval for pathogen reduction in platelets and plasma. For further details, visit Cerus Investor Relations.
Cerus Corporation (Nasdaq: CERS) has received permanent HCPCS Level II codes from CMS for its INTERCEPT Fibrinogen Complex (IFC) and Pathogen Reduced Plasma, effective October 1, 2021. These codes will aid hospitals in billing for these innovative products, enhancing access to transfusion medicine. Earlier, Cerus announced a new technology add-on payment for IFC within the Medicare Hospital Inpatient Prospective Payment System. The INTERCEPT Blood System, which also includes IFC, is designed for treating massive hemorrhage and has FDA Breakthrough Device designation.
Cerus Corporation (Nasdaq: CERS) has appointed Ann Lucena, CEO of San Ramon Regional Medical Center, to its Board of Directors. With a strong background in healthcare management, Lucena's experience is expected to add valuable insights from the provider community as Cerus aims to expand its blood safety product portfolio. Daniel Swisher, Chair of the Board, expressed enthusiasm for her addition, highlighting the ongoing paradigm shift in transfusion medicine and the importance of blood safety. Lucena's prior roles include Chief of Staff at Tenet Healthcare and healthcare consulting.
Cerus Corporation (Nasdaq: CERS) reported a strong second quarter of 2021, achieving total revenue of $37.8 million, a 41% year-over-year increase. Product revenue rose to $31.5 million, up 46% from 2020, driven by demand for INTERCEPT platelet products. The company has raised its annual product revenue guidance to $118-$122 million, marking a projected 28%-33% growth over 2020. Despite a net loss of $15.4 million for the quarter, the firm maintains healthy cash reserves of $123 million as of June 30, 2021.
Cerus Corporation (Nasdaq: CERS) announced that CMS has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex under the Medicare Hospital Inpatient Prospective Payment System (IPPS). The NTAP, applicable for patients with massive bleeding due to fibrinogen deficiency, allows additional payment of up to $2,535 per patient when costs exceed the MS-DRG payment. This decision supports improved access to this innovative blood product, enhancing care in urgent situations. The INTERCEPT Blood System for Cryoprecipitation received FDA Breakthrough Device designation and was approved in November 2020.
Cerus Corporation (Nasdaq: CERS) is set to release its second quarter 2021 financial results on August 3, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET, where management will discuss the financial outcomes and provide a business outlook. Investors can access the call via the Cerus Investor Relations website or through dedicated phone lines for U.S. and international participants. The replay will be available until August 17, 2021. Cerus is focused on enhancing blood safety through its INTERCEPT Blood System, with products approved in multiple regions.
Summary not available.